A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1222 participants.

Also called NCT06522997

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,222 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06522997
  • EU CT 2023-505755-40-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Belgium, China, Greece, India, Italy, Japan, Portugal, Singapore, Slovakia, Spain, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06522997. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-08 (actual); primary completion 2025-10-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
Acronym
ALPINE 1
Intervention (Drug)
BAY3283142
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct06522997
Content hash
7d24d0304e2343decd5609ec8cc965bb6161c405b6d274f026a1897c58968d81